- Home
- WOOF vs ARVN Comparison
WOOF vs ARVN Comparison
Compare WOOF & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WOOF | ARVN |
|---|---|---|
| Founded | 1965 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 871.9M | 781.0M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | WOOF | ARVN |
|---|---|---|
| Price | $2.68 | $10.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 20 |
| Target Price | $4.04 | ★ $15.35 |
| AVG Volume (30 Days) | ★ 3.9M | 670.7K |
| Earning Date | 03-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.11 | 58.84 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $5,961,467,000.00 | $262,600,000.00 |
| Revenue This Year | $2.73 | N/A |
| Revenue Next Year | $1.60 | N/A |
| P/E Ratio | $91.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.24 | $5.90 |
| 52 Week High | $4.19 | $14.22 |
Technical Indicators
Market Signals| Indicator | WOOF | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 45.16 | 31.91 |
| Support Level | $2.34 | $9.02 |
| Resistance Level | $3.26 | $10.18 |
| Average True Range (ATR) | 0.21 | 0.67 |
| MACD | -0.04 | -0.22 |
| Stochastic Oscillator | 26.17 | 4.18 |
Price Performance
Historical ComparisonAbout WOOF Petco Health and Wellness Company Inc.
Petco Health and Wellness Co Inc is a pet specialty retailer focused on improving the lives of pets, pet parents, and its own partners with pet care centers in approximately 50 states, the District of Columbia and Puerto Rico. The Company also offers an expanded range of consumables, supplies, and services through its website and mobile app.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.